The PRECISION trial demonstrates the superiority of MRI-targeted prostate bx (TB) over systematic biopsy (SB) in detection of clinically significant prostate cancer (csPCa) and avoidance of indolent disease by only performing TB in men with PI-RADS 3, 4 and 5 lesions on pre-biopsy MRI. In this study, we evaluate our outcomes using a contemporary cohort of men with comparable characteristics as the PRECISION study who underwent combined SB and MRI-US fusion targeted biopsy (MRF-TB) at our institution.
INTRODUCTION AND OBJECTIVES:
The PRECISION trial demonstrates the superiority of MRI-targeted prostate bx (TB) over systematic biopsy (SB) in detection of clinically significant prostate cancer (csPCa) and avoidance of indolent disease by only performing TB in men with PI-RADS 3, 4 and 5 lesions on pre-biopsy MRI. In this study, we evaluate our outcomes using a contemporary cohort of men with comparable characteristics as the PRECISION study who underwent combined SB and MRI-US fusion targeted biopsy (MRF-TB) at our institution.
METHODS: Between 1/2015 and 9/2018, a total of 1,329 biopsies were performed in 1,136 men after pre-biopsy MRI and outcomes were recorded in an IRB-approved prospective database. Biopsy results, indications, and PI-RADS were queried from those who underwent both MRF-TB and SB using the Artemis/Pro-fuse TM (Eigen, Grass Valley) co-registration system. csPCa was defined as at least one core with Gleason ! 3þ4 cancer.
RESULTS: A total of 450 men (age 64.5 AE 7.9 years, PSA 6.4 AE 3.2ng/mL) who underwent combined MRF-TB and SB met PRECISION study inclusion criteria (No prior biopsy, PSA 20ng/ml, pre-biopsy MRI with PI-RADS 3,4 or 5 lesions).
In our cohort, csPCa was detected in 235/450 (52%) of men with PI-RADS 3, 4 and 5 lesions by MRF-TB. This supports the csPCa detection rate of 55% (95/174) found in PRECISION.
If concurrent SB was not performed along with MRF-TB in these men, 46 PCa would be missed, with 18/46 (39%) considered csPCa, equivalent to missing 7% of the csPCa detected in the cohort. The percentage of csPCa missed with avoidance of SB is strongly dependent on PI-RADS (Table 1) .
CONCLUSIONS: In a cohort of men with comparable clinical characteristics to the PRECISION trial, we found similar csPCa detection among men with PI-RADS 3, 4 and 5 lesions. While avoidance of SB misses few csPCa in men with PI-RADS 4 and 5 lesions, a larger proportion of csPCa (17%) is missed in men with PI-RADS 3 lesions with MRF-TB alone. Further studies are necessary to identify the optimal population in whom SB can be safely avoided.
Source of Funding: Joseph and Diane Steinberg Charitable Fund

MP36-09 DIAGNOSTIC ACCURACY OF TARGETED PROSTATE BIOPSIES: RESULTS FROM A PROSPECTIVE TRIAL COMPARING MICRO-ULTRASOUND WITH MULTIPARAMETRIC MRI FOR THE DETECTION OF PROSTATE CANCER
Davide Maffei*, Marco Paciotti, Massimo Lazzeri, Piergiuseppe Colombo, Vittorio Fasulo, Luigi Domanico, Paolo Casale, Alberto Saita, Rodolfo Hurle, Nicol o Maria Buffi, Giorgio Ferruccio Guazzoni, Giovanni Lughezzani, Rozzano, Italy INTRODUCTION AND OBJECTIVES: Targeted multiparametric MRI (mpMRI) fusion biopsies have gained a significant role in the prostate cancer (PCa) diagnostic pathway. High-resolution micro-ultrasound (mUS) is a new real-time US-based imaging modality enabling real-time targeted prostate biopsies. We examined the efficacy of mUS as a newly found diagnostic approach to targeted biopsies and subsequently compared it to mpMRI within a prospectively collected cohort of men with suspected PCa.
METHODS: The study population consisted of 179 patients with at least 1 suspicious lesion (PIRADSv2!3) according to mpMRI who were enrolled within a prospective trial aimed at comparing the diagnostic accuracy of mUS and mpMRI.
The PRI-MUS risk identification protocol was used to identify targets on mUS. The urologist, newly trained on performing mUS targeted-biopsies, was blinded to mpMRI results until after mUS targeting was complete. All subjects received targeted biopsy (based on mUS and mpMRI imaging) as well as systematic random biopsies. The overall presence of PCa and clinically significant (Gleason score ! 7) PCa was assessed. Concordance between mpMRI and mUS findings and biopsy results were determined.
RESULTS: Mean patient age was 64.7 yrs and mean total PSA value was 8.2 ng/mL. Overall, 92 (51.4%) patients were in the repeat biopsy setting. PCa detection rate was 56.5%, while csPCa detection rate was 38.0%. The proportion of patients with csPCa increased significantly according to PRIMUS (from 16.7 to 41.0 and 60.5% for patients with a PRIMUS score 3, 4 and 5 lesion, respectively; p<0.001), and to PIRADS score (from 17.9 to 39.0 and 54.8% in patients with a PIRADS score 3,4 and 5 lesion, respectively; p[0.007). mUS csPCa sensitivity was 91.2% (62/68 with csPCa having !1 lesion at mUS). Negative predictive value was 82.4%, while positive predictive value was 42.8% and specificity was 25.2%. Overall, 111 concordant target zones between mUS and mpMRI were identified, in which 50 were csPCa. Although presenting with suspicious lesions at both mpMRI and mUS, 6 patients (5 in the initial biopsy setting) were diagnosed with csPCa by random cores only.
CONCLUSIONS: mUS is a promising imaging modality for targeted biopsies. It may provide additional information regarding the presence or absence of csPCa in patients with suspected PCa according to mpMRI and further improve results over conventional MRI/ US fusion biopsy. Further studies are warranted to investigate how the new mUS modality can best be leveraged within the PCa diagnostic pathway.
Source of Funding: none
MP36-10 WHO BENEFITS FROM MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING AFTER THE SUSPICION OF PROSTATE CANCER?
Merce Cuadras*, Ana Celma, Lucas Regis, Aina Salazar, Enric Miret, Sarai Roche, Ines M. de Torres, Richard Mast, Maria E. Semidey, Jacques Planas, Juan Morote, Barcelona, Spain INTRODUCTION AND OBJECTIVES: The suspicion of prostate cancer (PCa) is based onserum prostatic specific antigen (PSA) elevation and/or an abnormal digital rectal examination (DRE). Multiparametric magnetic resonance imaging (mpMRI) can increase the specificity of prostatic biopsy (PBx) and its sensitivity for aggressive tumours.
Our objective was to know the benefit of mpMRI according to the type of biopsy (initial vs repeated) and PSA-DRE related groups (G1: PSA <10 & -DRE, G2: PSA <10 & þDRE, G3: PSA >10 & -DRE, and G4: PSA >10 & þDRE).
METHODS: 768 consecutive men scheduled to undergo PBx between 2016 and 2017 at a single tertiary institution underwent pelvic 3 Tesla (3T) mpMRI scanning, 12-core transrectal ultrasound (TRUS)-guided systematic biopsy (SBx) and mpMRI-TRUS targeted biopsies (TBx) due to suspicious lesions (PIRADS v.2 >3). Outcome variables were: Avoidable biopsies (PIRADS <3), missing high-grade PCa (HGPCa: ISUP >1) when the mpMRI is negative, and increase of HGPCa diagnosis due to TBx.
RESULTS: The overall rate of avoidable biopsies was 24.2%: 25.7% of initial biopsies (IBx) and 20.5% for repeated biopsies (RBx), p [0.057. These rates were 31.2% and 19.8%, respectively in G1; 13.5% and 30.4%, respectively in in G2; 23.7% and 21.9%, respectively in G3; and 2.5% and 0%, respectively in G4. The rate of missed HGPCa was 1.0% with the IBx and 6.5% for the RBx (p [0.170). It was 1.1% and 5.2%, 2.0% and 11.1%, 0% and 7.7%, and 0% and 0%, respectively from G1 to G4: p <0.001. The rate of HGPCa diagnosed following Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e517
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